HIGH POINT, N.C.--(BUSINESS WIRE)--vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage biopharmaceutical company engaged in the discovery and development of new orally administered treatments for Alzheimer’s disease and diabetes, today announced that company Chief Medical Officer Dr. Larry Altstiel, MD, PhD will be giving a platform presentation titled “Clinical Support for Advancement of the RAGE Antagonist Azeliragon into Phase 3 Clinical Investigation for Mild Alzheimer’s Disease” at the International Psychogeriatric Association International Congress on Wednesday, September 7 between 10:00 and 11:30am.
